Detailed Narrative
Q1 FY26 Financial Performance Overview
Blue Jet Healthcare reported a strong Q1 FY26, with revenue from operations reaching ₹354.8 crores, marking a 4% sequential increase and a significant 118% year-on-year growth. EBITDA stood at ₹121 crores, translating to a 34% margin, and growing 178% YoY. Profit After Tax (PAT) was ₹91.2 crores, with a net margin of 25.7%, up 114% YoY. The company attributed this performance to consistent volume growth across its Pharma Intermediates (PI), API, and contrast media platforms.
Gross Margin Dynamics and Inventory Impact
The gross margin for Q1 FY26 was 48.5%, a 6.5% decline from 55% in Q4 FY25. Management explained that this was primarily due to a ₹75 crore reduction in finished goods and WIP inventory, which released associated overheads into the P&L. Approximately 4.4% of the decline was attributed to this inventory adjustment, and 2.1% to product mix changes. Management stated that the underlying gross margin, when considering Q4 and Q1 cumulatively, was 53% and expected to be sustained in coming quarters.
Capacity Expansion and Strategic Investments
The company's new CDMO capacity at Unit-2 Ambernath is fully operational, currently at 60% utilization. Construction at Unit-3 Mahad, focused on backward integration for the CMI segment and designed for continuous processing, is on schedule for H2 FY26 commissioning. The CAPEX for Unit-3 Mahad has been revised upwards from ₹250 crores to ₹300 crores, with ₹100 crores already incurred and the balance ₹200 crores to be spent by FY27. Additionally, a new R&D center is being built at a cost of ₹40 crores, focusing on peptides and GLP-1 intermediates.
Future Growth and Pipeline Opportunities
Blue Jet Healthcare plans to add another 1,000 KL of manufacturing capacity over the next 2-3 years, supported by the acquisition of a large land parcel for a new CDMO facility. The company is tracking 20 new R&D opportunities, with 6 already in late Phase III or commercial stages. Management highlighted structural tailwinds from global supply chain de-risking and increasing adoption of complex APIs and NCE intermediates, particularly in contrast media with new molecules under validation.
Segment Performance and Outlook
The PI and API segment grew 8.2% quarter-on-quarter, while artificial sweeteners saw a 17.4% QoQ growth, recovering from a muted FY25. The contrast media segment experienced a 3.9% QoQ dip due to phasing but has a positive outlook with new iodinated intermediates and gadolinium-based products planned for commercialization this quarter. Management expressed aspiration to return the contrast media segment to FY23 revenue levels (approx. ₹500 crores) by FY25 or FY26.
CDMO Business and Asset Turn Targets
The CDMO business is seeing increased traction, with 20 RFPs currently, up from 11-12 last year, including 6 in late Phase III or commercial. The company is focusing on peptide fragments and amino acid derivatives, with 45 peptide fragments already developed. Management stated that the company's overall asset turn is currently 'north of four' and is projected to be 'somewhere close to 2.5 to 3' over the next five years, reflecting the significant CAPEX investments.